[
  {
    "0": {
      "companyName": "NEOPHARM",
      "documentType": "Investor Relations",
      "year": 2024,
      "mainTitleEnglish": "The Global Leader In Skin Science",
      "mainTitleKorean": "피부 과학의 선도기업",
      "keywords": [
        "Skin Science",
        "Global Leader",
        "Investor Relations"
      ]
    }
  },
  {
    "1": {
      "company_name_en": "NEOPHARM",
      "company_name_ko": "네오팜",
      "slogan_en": "The Global Leader In Skin Science",
      "slogan_ko": "피부 과학의 선도기업",
      "company_description_ko": "네오팜은 피부과학의 선도기업으로서, 끊임없는 기술혁신으로 인류공헌에 앞장섭니다.",
      "section_title_en": "Earnings Summary",
      "section_subtitles_ko": [
        "매출 및 손익 현황",
        "주요 채널별 매출 현황",
        "주요 제품군 매출 현황"
      ],
      "products": [
        {
          "brand": "ATOPALM",
          "name_en": "MLE CREAM",
          "name_ko": "엠엘이 크림",
          "description_en": "MLE Skin Barrier Cream",
          "description_ko": "MLE 피부보호막 가능성 크림",
          "features_ko": [
            "기능성 화장품"
          ]
        },
        {
          "brand": "ATOPALM",
          "name_en": "MLE LOTION",
          "name_ko": "MLE 로션",
          "description_en": "MLE Skin Barrier Lotion",
          "description_ko": "수분 보습막 기능성 로션",
          "features_ko": []
        },
        {
          "brand": "ATOPALM",
          "name_en": "PANTHENOL CREAM",
          "name_ko": "판테놀 크림",
          "description_en": "Intensive Deep-Hydration Calming Cream",
          "description_ko": "집중 고보습 진정 크림",
          "features_ko": []
        },
        {
          "brand": "ATOPALM",
          "name_en": "PANTHENOL STICK BALM",
          "name_ko": "판테놀 스틱 밤",
          "description_en": "Calming Stick Balm For Sensitive Areas",
          "description_ko": "민감 부위 진정 스틱 밤",
          "features_ko": []
        },
        {
          "brand": "ATOPALM",
          "name_en": "TOP TO TOE WASH",
          "name_ko": "팝투토 워시",
          "description_en": "Moisturising Shampoo & Body Wash",
          "description_ko": "세정 후에도 촉촉한 샴푸 겸용 바스",
          "features_ko": []
        },
        {
          "brand": "ATOPALM",
          "name_en": "FACIAL FOAM WASH",
          "name_ko": "페이셜 폼 워시",
          "description_en": "pH Balanced Bubble Cleanser",
          "description_ko": "pH 밸런스 약산성 버블 클렌저",
          "features_ko": []
        }
      ]
    }
  },
  {
    "2": {
      "company_name": "NEOPHARM",
      "report_year": "2024",
      "report_quarter": "Q2",
      "report_title": "2024년 2분기 경영성과 매출 및 손익 현황 (연결)",
      "financial_metrics": [
        {
          "metric_name": "매출",
          "value_2024_q2": "306",
          "unit_2024_q2": "억원",
          "yoy_change_rate": "+25.0%",
          "summary": "비중국 중심 수출 성장 지속",
          "detailed_values": [
            {
              "year_quarter": "2023 2Q",
              "value": "24498",
              "unit": "백만원"
            },
            {
              "year_quarter": "2024 2Q",
              "value": "30621",
              "unit": "백만원"
            }
          ]
        },
        {
          "metric_name": "영업이익",
          "value_2024_q2": "61",
          "unit_2024_q2": "억원",
          "yoy_change_rate": "-2.7%",
          "summary": "매출 믹스에 따른 원가 상승 영향",
          "detailed_values": [
            {
              "year_quarter": "2023 2Q",
              "value": "6273",
              "unit": "백만원"
            },
            {
              "year_quarter": "2024 2Q",
              "value": "6107",
              "unit": "백만원"
            }
          ]
        },
        {
          "metric_name": "순이익",
          "value_2024_q2": "58",
          "unit_2024_q2": "억원",
          "yoy_change_rate": "+7.6%",
          "summary": "외화환산이익 증가 영향",
          "detailed_values": [
            {
              "year_quarter": "2023 2Q",
              "value": "5469",
              "unit": "백만원"
            },
            {
              "year_quarter": "2024 2Q",
              "value": "5883",
              "unit": "백만원"
            }
          ]
        }
      ]
    }
  },
  {
    "3": {
      "report_title": "2024년 2분기 경영성과 주요 채널별 매출 현황 (별도)",
      "period": "2024 2Q",
      "sales_by_channel": [
        {
          "channel_type": "Online",
          "key_channels": "외부몰, 자사몰 등",
          "sales_amount_krw": "88억",
          "sales_percentage": "29%",
          "yoy_growth_rate_percentage": "역성장"
        },
        {
          "channel_type": "Offline",
          "key_channels": "병의원, H&B 등",
          "sales_amount_krw": "174억",
          "sales_percentage": "57%",
          "yoy_growth_rate_percentage": "53% 성장"
        },
        {
          "channel_type": "Export",
          "key_channels": "미주/아시아/중국/기타",
          "sales_amount_krw": "44억",
          "sales_percentage": "14%",
          "yoy_growth_rate_percentage": "22% 성장"
        }
      ]
    }
  },
  {
    "4": {
      "report_title": "2024년 2분기 경영성과 주요 제품군 매출 현황 (별도)",
      "period": "2024 2분기",
      "unit_for_sales_trend": "백만원",
      "product_categories_summary": [
        {
          "category": "Skin Care",
          "main_brands": [
            "아토팜",
            "제로이드"
          ],
          "sales_amount_billion_krw": 173,
          "sales_ratio_percent": 57,
          "yoy_growth_percent": 6,
          "yoy_growth_description": "성장"
        },
        {
          "category": "Facial Care",
          "main_brands": [
            "리얼베리어",
            "티엘스"
          ],
          "sales_amount_billion_krw": 33,
          "sales_ratio_percent": 11,
          "yoy_growth_percent": null,
          "yoy_growth_description": "역성장"
        },
        {
          "category": "Body Care",
          "main_brands": [
            "더마비"
          ],
          "sales_amount_billion_krw": 48,
          "sales_ratio_percent": 16,
          "yoy_growth_percent": 38,
          "yoy_growth_description": "성장"
        },
        {
          "category": "Others",
          "main_brands": [
            "OEM 및 기타 브랜드"
          ],
          "sales_amount_billion_krw": 51,
          "sales_ratio_percent": 17,
          "yoy_growth_percent": 467,
          "yoy_growth_description": "성장"
        }
      ],
      "sales_trend_by_quarter": [
        {
          "quarter": "2023 2Q",
          "skin_care_sales_amount_million_krw": 16400,
          "facial_care_sales_amount_million_krw": 3645,
          "body_care_sales_amount_million_krw": 3498,
          "others_sales_amount_million_krw": 903
        },
        {
          "quarter": "2023 3Q",
          "skin_care_sales_amount_million_krw": 13529,
          "facial_care_sales_amount_million_krw": 3252,
          "body_care_sales_amount_million_krw": 3649,
          "others_sales_amount_million_krw": 1400
        },
        {
          "quarter": "2023 4Q",
          "skin_care_sales_amount_million_krw": 16148,
          "facial_care_sales_amount_million_krw": 3901,
          "body_care_sales_amount_million_krw": 5095,
          "others_sales_amount_million_krw": 2084
        },
        {
          "quarter": "2024 1Q",
          "skin_care_sales_amount_million_krw": 16224,
          "facial_care_sales_amount_million_krw": 3968,
          "body_care_sales_amount_million_krw": 4641,
          "others_sales_amount_million_krw": 3395
        },
        {
          "quarter": "2024 2Q",
          "skin_care_sales_amount_million_krw": 17365,
          "facial_care_sales_amount_million_krw": 3352,
          "body_care_sales_amount_million_krw": 4840,
          "others_sales_amount_million_krw": 5125
        }
      ]
    }
  },
  {
    "5": {
      "company_information": {
        "name": "NEOPHARM",
        "slogan": {
          "english": "The Global Leader In Skin Science",
          "korean": "피부 과학의 선도기업 네오팜"
        },
        "description": {
          "korean": "네오팜은 피부과학의 선도기업으로서, 끊임없는 기술혁신으로 인류공헌에 앞장섭니다."
        }
      },
      "document_sections": [
        {
          "title_english": "Appendix",
          "title_korean": "재무 사항"
        }
      ],
      "product_lines": [
        {
          "brand": "Realbarrier",
          "line_name": "EXTREME",
          "products": [
            {
              "product_name": {
                "english": "EXTREME CREAM",
                "korean": "익스트림 크림"
              },
              "variants": [
                {
                  "type": "Light",
                  "volume": "70ml/2.36fl.oz."
                },
                {
                  "type": "Light",
                  "volume": "65ml/2.19fl.oz."
                },
                {
                  "type": "Original",
                  "volume": "70ml/2.36fl.oz."
                }
              ]
            }
          ]
        },
        {
          "brand": "Realbarrier",
          "line_name": "AQUA SOOTHING",
          "products": [
            {
              "product_name": {
                "english": "AQUA SOOTHING AMPOULE MASK",
                "korean": "아쿠아 수딩 앰플 마스크"
              },
              "variants": [
                {
                  "type": null,
                  "volume": "28ml/0.94fl.oz."
                }
              ]
            },
            {
              "product_name": {
                "english": "AQUA SOOTHING TONER",
                "korean": "아쿠아 수딩 토너"
              },
              "variants": [
                {
                  "type": null,
                  "volume": null
                }
              ]
            },
            {
              "product_name": {
                "english": "AQUA SOOTHING CREAM",
                "korean": "아쿠아 수딩 크림"
              },
              "variants": [
                {
                  "type": null,
                  "volume": null
                }
              ]
            }
          ]
        }
      ]
    }
  },
  {
    "6": {
      "unit": "억원",
      "statement_of_financial_position": {
        "current_assets": {
          "2020": 1136,
          "2021": 1215,
          "2022": 1313,
          "2023": 1345
        },
        "non_current_assets": {
          "2020": 194,
          "2021": 219,
          "2022": 241,
          "2023": 430
        },
        "total_assets": {
          "2020": 1330,
          "2021": 1434,
          "2022": 1553,
          "2023": 1775
        },
        "current_liabilities": {
          "2020": 149,
          "2021": 129,
          "2022": 131,
          "2023": 169
        },
        "non_current_liabilities": {
          "2020": 4,
          "2021": 2,
          "2022": 0,
          "2023": 5
        },
        "total_liabilities": {
          "2020": 153,
          "2021": 131,
          "2022": 131,
          "2023": 174
        },
        "capital_stock": {
          "2020": 41,
          "2021": 41,
          "2022": 41,
          "2023": 41
        },
        "capital_surplus": {
          "2020": 451,
          "2021": 457,
          "2022": 457,
          "2023": 457
        },
        "capital_adjustments": {
          "2020": -26,
          "2021": -32,
          "2022": -32,
          "2023": -32
        },
        "accumulated_other_comprehensive_income": {
          "2020": 0,
          "2021": -1,
          "2022": -5,
          "2023": -2
        },
        "retained_earnings": {
          "2020": 711,
          "2021": 838,
          "2022": 961,
          "2023": 1136
        },
        "total_equity": {
          "2020": 1177,
          "2021": 1303,
          "2022": 1422,
          "2023": 1600
        }
      },
      "statement_of_comprehensive_income": {
        "sales_revenue": {
          "2020": 816,
          "2021": 879,
          "2022": 850,
          "2023": 971
        },
        "cost_of_sales": {
          "2020": 230,
          "2021": 255,
          "2022": 267,
          "2023": 317
        },
        "gross_profit": {
          "2020": {
            "value": 586,
            "ratio": "72%"
          },
          "2021": {
            "value": 624,
            "ratio": "71%"
          },
          "2022": {
            "value": 584,
            "ratio": "69%"
          },
          "2023": {
            "value": 654,
            "ratio": "67%"
          }
        },
        "selling_and_administrative_expenses": {
          "2020": 367,
          "2021": 400,
          "2022": 369,
          "2023": 401
        },
        "operating_profit": {
          "2020": {
            "value": 219,
            "ratio": "27%"
          },
          "2021": {
            "value": 224,
            "ratio": "26%"
          },
          "2022": {
            "value": 214,
            "ratio": "25%"
          },
          "2023": {
            "value": 253,
            "ratio": "26%"
          }
        },
        "non_operating_income": {
          "2020": 17,
          "2021": 20,
          "2022": 25,
          "2023": 49
        },
        "non_operating_expenses": {
          "2020": 6,
          "2021": 6,
          "2022": 6,
          "2023": 8
        },
        "profit_before_income_tax": {
          "2020": 229,
          "2021": 238,
          "2022": 233,
          "2023": 294
        },
        "income_tax_expense": {
          "2020": 48,
          "2021": 61,
          "2022": 63,
          "2023": 62
        },
        "net_profit": {
          "2020": {
            "value": 181,
            "ratio": "22%"
          },
          "2021": {
            "value": 177,
            "ratio": "20%"
          },
          "2022": {
            "value": 170,
            "ratio": "20%"
          },
          "2023": {
            "value": 232,
            "ratio": "24%"
          }
        }
      }
    }
  },
  {
    "7": {
      "company_name": "주식회사 네오팜",
      "address": "대전광역시 유성구 테크노로 309-8",
      "tel_number": "042-864-0043",
      "fax_number": "042-864-0039",
      "website": "www.neopharm.co.kr"
    }
  }
]